Encompass Health has opened a new 50-bed inpatient rehabilitation hospital in Bangor, Maine, providing specialized care for patients recovering from strokes, brain injuries, spinal cord injuries, amputations, and complex orthopedic conditions. The facility offers intensive therapy, physician visits, and 24-hour nursing care to help patients regain independence and improve quality of life. This new hospital expands access to high-quality rehabilitation services in the Northeast and helps reduce pressure on local acute care hospitals. It is Encompass Health's first wholly owned hospital in Maine, complementing its joint venture hospital in Portland.
Encompass Health Rehabilitation Hospital of Bangor opening is noted alongside Pluang's health sector data. For readers following US health stocks, 47 out of 100 rose while 53 fell as of Oct 07, 2026 03:04 WIB. Notable movers include DNA at USD 12.49 with a -16.62% change and a typical hold time of 7 days, HRTX at USD 0.32 down 12.95%, and NVAX at USD 11.31 down 9.95%.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
Evercore ISI raised its price target for Marvell Technology to $433 from $275, maintaining an Outperform rating. This follows Marvell's optimistic revenue projections, expecting $20 billion by fiscal 2028 and $70-$90 billion by fiscal 2031, driven by...
